Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects - Vandell, Alexander G.; Inoue, Satoshi; Dennie, Justin; Nagasawa, Yasuo; Gajee, Roohi; Pav, Joe; Zhang, George; Zamora, Cynthia; Masuda, Nobuhisa; Senaldi, Giorgio (Antimicrobial Agents and Chemotherapy, 2018)
Keywords: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Bacteroides fragilis; Bifidobacterium; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Drug Administration Schedule; Experimental Therapeutics; Female; Gastrointestinal Microbiome; Healthy Volunteers; Humans; Male; Middle Aged; Prevotella; Topoisomerase II Inhibitors; Young Adult; DS-2969b; antibiotic; infection; antimicrobial agents; Clostridium difficile